Search results

  1. Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximab.

    … parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximab. …

  2. The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma.

    … and patient characteristics on survival in plasmablastic lymphoma. Journal …

  3. Diffuse large B-cell lymphoma.

    Diffuse large B-cell lymphoma. Journal …

  4. INCMOR0208-301 (LYTMOR0208)

    … in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma Drug Name …

  5. Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma.

    … as Frontline Therapy in Older Adults With Hodgkin Lymphoma. Journal …

  6. Recipients of Round Two of the 2024 BC Cancer Clinician Researcher Start Up Competition Announced

    … of the Intestinal Microbiome in Patients with Mantle Cell Lymphoma Juanita Crook (BC Cancer – Kelowna): …

    Dec 3, 2024

  7. Lymphoid Cancer Research

    … patient outcomes by gaining a deeper understanding of lymphoma biology and progression, for use in clinical …

  8. Clinical Trials

    … tongue Hematology (blood cancer) includes leukemia, lymphoma and multiple myeloma     BC Cancer …

  9. LY.17 (LYLY17)

    … the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma Cancer …

  10. DS3201-A-U202 (LYTAU202)

    … in Subjects with Relapsed/Refractory Peripheral T-Cell Lymphoma  Cancer …

Back to top